CYCC Insider Trading
Insider Ownership Percentage: 68.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $5,838,864.60
Cyclacel Pharmaceuticals Share Price & Price History
Current Price: $0.28
Price Change: ▲ Price Increase of +0.0495 (21.62%)
As of 04/25/2025 05:00 PM ET
Cyclacel Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/26/2025 | David E. Lazar | CEO | Sell | 194,628,820 | $0.03 | $5,838,864.60 | |  |
| 12/21/2023 | Paul Mcbarron | Insider | Buy | 1,886 | $3.31 | $6,242.66 | 33,378 | |
| 12/21/2023 | Spiro George Rombotis | CEO | Buy | 6,070 | $3.31 | $20,091.70 | 68,658 | |
Cyclacel Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/15/2024 | Armistice Capital LLC | 134,000 | $0.22M | 0.0% | N/A | 9.178% |  |
| 5/10/2024 | Acadian Asset Management LLC | 14,285 | $29K | 0.0% | -41.0% | 1.084% | |
| 11/1/2022 | Kestra Advisory Services LLC | 23,000 | $34K | 0.0% | N/A | 0.183% | |
| 10/25/2022 | Raymond James Financial Services Advisors Inc. | 20,806 | $30K | 0.0% | -32.5% | 0.166% | |
| 10/18/2022 | McIlrath & Eck LLC | 26,342 | $38K | 0.0% | N/A | 0.210% | |
| 8/15/2022 | Sio Capital Management LLC | 454,355 | $0.49M | 0.2% | +7.5% | 4.546% | |
| 2/10/2022 | Acadian Asset Management LLC | 23,242 | $89K | 0.0% | N/A | 0.233% | |
| 11/16/2021 | Two Sigma Advisers LP | 121,500 | $0.64M | 0.0% | +929.7% | 1.316% | |
| 11/15/2021 | Pura Vida Investments LLC | 105,141 | $0.55M | 0.0% | -33.2% | 1.139% | |
| 11/15/2021 | Tri Locum Partners LP | 522,943 | $2.76M | 1.1% | +66.9% | 5.663% | |
| 11/12/2021 | Affinity Asset Advisors LLC | 400,000 | $2.11M | 0.5% | +5.3% | 4.332% | |
| 11/2/2021 | Raymond James Financial Services Advisors Inc. | 10,006 | $53K | 0.0% | -83.3% | 0.108% | |
| 10/15/2021 | NEXT Financial Group Inc | 14,752 | $77K | 0.0% | +70.0% | 0.160% | |
| 8/18/2021 | Ikarian Capital LLC | 100,000 | $0.59M | 0.0% | -66.7% | 1.083% | |
| 8/17/2021 | Boothbay Fund Management LLC | 10,545 | $62K | 0.0% | -66.7% | 0.114% | |
| 8/17/2021 | Citadel Advisors LLC | 250,797 | $1.49M | 0.0% | -14.7% | 2.716% | |
| 8/16/2021 | Tri Locum Partners LP | 313,331 | $1.86M | 0.6% | +6.8% | 3.393% | |
| 8/16/2021 | Schonfeld Strategic Advisors LLC | 102,525 | $0.61M | 0.0% | -25.0% | 1.110% | |
| 8/16/2021 | Maven Securities LTD | 234,500 | $1.43M | 0.1% | -6.2% | 2.540% | |
| 8/13/2021 | Northern Trust Corp | 14,957 | $89K | 0.0% | N/A | 0.162% | |
| 8/13/2021 | Geode Capital Management LLC | 50,860 | $0.30M | 0.0% | +143.3% | 0.551% | |
| 8/13/2021 | Vanguard Group Inc. | 327,658 | $1.94M | 0.0% | +9.2% | 3.548% | |
| 7/31/2021 | NEXT Financial Group Inc | 8,680 | $51K | 0.0% | N/A | 0.094% | |
| 5/19/2021 | Virtu Financial LLC | 13,108 | $93K | 0.0% | +27.3% | 0.142% | |
| 5/19/2021 | Squarepoint Ops LLC | 23,836 | $0.17M | 0.0% | N/A | 0.258% | |
| 5/18/2021 | Point72 Asset Management L.P. | 230,000 | $1.64M | 0.0% | N/A | 2.491% | |
| 5/18/2021 | Verition Fund Management LLC | 116,674 | $0.83M | 0.0% | N/A | 1.264% | |
| 5/18/2021 | Morgan Stanley | 100,000 | $0.71M | 0.0% | -13.0% | 1.083% | |
| 5/18/2021 | Citadel Advisors LLC | 293,867 | $2.09M | 0.0% | N/A | 3.182% | |
| 5/18/2021 | Silverarc Capital Management LLC | 250,000 | $1.78M | 1.0% | N/A | 2.707% | |
| 5/17/2021 | Schonfeld Strategic Advisors LLC | 136,725 | $0.97M | 0.0% | N/A | 1.481% | |
| 5/17/2021 | Sphera Funds Management LTD. | 508,322 | $3.61M | 0.3% | N/A | 5.505% | |
| 5/17/2021 | Ikarian Capital LLC | 300,000 | $2.13M | 0.1% | -23.4% | 3.249% | |
| 5/12/2021 | Geode Capital Management LLC | 20,904 | $0.15M | 0.0% | N/A | 0.226% | |
| 5/12/2021 | Pura Vida Investments LLC | 273,958 | $1.95M | 0.1% | -42.3% | 2.967% | |
| 5/11/2021 | Acadian Asset Management LLC | 34,057 | $0.24M | 0.0% | N/A | 0.369% | |
Data available starting January 2016
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Read More on Cyclacel Pharmaceuticals
Volume
3,723,147 shs
Average Volume
1,229,871 shs
Market Capitalization
$57.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.15
Who are the company insiders with the largest holdings of Cyclacel Pharmaceuticals?
